Urologists, You'll Never Walk Alone! How Novel Immunotherapy and Modern Imaging May Change the Management of Non-muscle-invasive Bladder Cancer.


Journal

European urology oncology
ISSN: 2588-9311
Titre abrégé: Eur Urol Oncol
Pays: Netherlands
ID NLM: 101724904

Informations de publication

Date de publication:
06 2022
Historique:
received: 17 05 2021
accepted: 27 05 2021
pubmed: 21 6 2021
medline: 9 6 2022
entrez: 20 6 2021
Statut: ppublish

Résumé

Novel immune checkpoint inhibitors hold promise for non-muscle-invasive bladder cancer. Cooperation between urologists and other multidisciplinary bladder cancer specialists can surmount the challenges involved in using these agents in bladder-sparing approaches. This strategy could deliver a new era of comprehensive evaluation and multimodal treatment for this patient population.

Identifiants

pubmed: 34147473
pii: S2588-9311(21)00114-0
doi: 10.1016/j.euo.2021.05.008
pii:
doi:

Substances chimiques

Immune Checkpoint Inhibitors 0

Types de publication

Editorial

Langues

eng

Sous-ensembles de citation

IM

Pagination

268-272

Informations de copyright

Copyright © 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Gianluca Giannarini (G)

Urology Unit, Santa Maria della Misericordia University Hospital, Udine, Italy. Electronic address: gianluca.giannarini@hotmail.it.

Neeraj Agarwal (N)

Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

Andrea B Apolo (AB)

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Alberto Briganti (A)

Urology Unit, IRCCS San Raffaele Scientific Institute, Vita Salute University, Milan, Italy; Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Petros Grivas (P)

Department of Medicine, Division of Medical Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, USA.

Shilpa Gupta (S)

Department of Hematology/Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Ashish M Kamat (AM)

Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Francesco Montorsi (F)

Urology Unit, IRCCS San Raffaele Scientific Institute, Vita Salute University, Milan, Italy; Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Morgan Rouprêt (M)

GRC 5 Predictive Onco-Uro, Sorbonne University, Urology, Pitié-Salpêtrière Hospital AP-HP, Paris, France.

Andrea Necchi (A)

Urology Unit, IRCCS San Raffaele Scientific Institute, Vita Salute University, Milan, Italy; Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy; Department of Medical Oncology, IRCCS San Raffaele Scientific Institute, Vita Salute University, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH